CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 13, 2006--CombinatoRx, Incorporated (NASDAQ: CRXX - News) today announced that additional results of its randomized, blinded, placebo-controlled phase 2 clinical trial of CRx-102 in patients with osteoarthritis (OA) of the hand will be featured at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology Meeting, June 21-24, 2006 in Amsterdam, The Netherlands. A poster will be presented by Dr. Tore Kvien entitled “Efficacy and Safety of a Novel Syncretic Drug Candidate - CRx-102 - in Hand Osteoarthritis” (Abstract THUO396) on Thursday, June 22, 12:15-2:00pm, and a satellite symposium entitled “Treatment of Chronic Inflammatory Diseases - Current and Future Paradigms” which is co-chaired by Paul Emery, MD, Professor of Rheumatology, Leeds Teaching Hospitals, Leeds, UK and Tore Kvien, MD, Professor of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, will be held on Saturday, June 24 at 10:15-11:45am in Room A.
